November 27, 2013
Eisai will take over the Japanese marketing authorization holder license for Gliadel 7.7 mg Implant (carmustine), an antineoplastic agent used during malignant glioma surgeries, from Nobelpharma on December 2. The two partners will still continue their joint promotion for Gliadel,...read more